Loading stock data…
$0.93-0.00 (-0.48%)
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States.
Phio Pharmaceuticals Corp. in the Healthcare sector is trading at $0.93 with a market capitalization of $12M. Wall Street consensus targets $14.00 (1 analysts), implying a +1405.4% move over the next 12 months. The stock is currently near its 52-week low of $0.81, remaining 15.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.27M↓ | -$4.17M↓ | -$2.53M↓ | -$2.50M↓ | -$2.31M |
| Net Income | -$4.14M↓ | -$4.00M↓ | -$2.37M↑ | -$2.39M↓ | -$2.17M |
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center...